Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity

Cisplatin is a widely used drug in the treatment of various solid tumors, such as ovarian cancer. However, while the acquired resistance significantly limits the success of therapy, some tumors, such as colorectal cancer, are intrinsically insensitive to cisplatin. Only a small amount of intracellul...

Full description

Bibliographic Details
Main Authors: Sophie Möltgen, Eleonora Piumatti, Giuseppe M. Massafra, Sabine Metzger, Ulrich Jaehde, Ganna V. Kalayda
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/9/6/1322
_version_ 1797567036668248064
author Sophie Möltgen
Eleonora Piumatti
Giuseppe M. Massafra
Sabine Metzger
Ulrich Jaehde
Ganna V. Kalayda
author_facet Sophie Möltgen
Eleonora Piumatti
Giuseppe M. Massafra
Sabine Metzger
Ulrich Jaehde
Ganna V. Kalayda
author_sort Sophie Möltgen
collection DOAJ
description Cisplatin is a widely used drug in the treatment of various solid tumors, such as ovarian cancer. However, while the acquired resistance significantly limits the success of therapy, some tumors, such as colorectal cancer, are intrinsically insensitive to cisplatin. Only a small amount of intracellular platinum binds to the target—genomic DNA. The fate of the remaining drug is largely obscure. This work aimed to identify the cytosolic protein binding partners of cisplatin in ovarian and colorectal cancer cells and to evaluate their relevance for cell sensitivity to cisplatin and oxaliplatin. Using the fluorescent cisplatin analog BODIPY-cisplatin, two-dimensional gel electrophoresis, and mass spectrometry, we identified the protein binding partners in A2780 and cisplatin-resistant A2780cis ovarian carcinoma, as well as in HCT-8 and oxaliplatin-resistant HCT-8ox colorectal cell lines. Vimentin, only identified in ovarian cancer cells; growth factor receptor-bound protein 2, only identified in colorectal cancer cells; and glutathione-S-transferase π, identified in all four cell lines, were further investigated. The effect of pharmacological inhibition and siRNA-mediated knockdown on cytotoxicity was studied to assess the relevance of these binding partners. The silencing of glutathione-S-transferase π significantly sensitized intrinsically resistant HCT-8 and HCT-8ox cells to cisplatin, suggesting a possible involvement of the protein in the resistance of colorectal cancer cells to the drug. The inhibition of vimentin with FiVe1 resulted in a significant sensitization of A2780 and A2780cis cells to cisplatin, revealing new possibilities for improving the chemosensitivity of ovarian cancer cells.
first_indexed 2024-03-10T19:35:54Z
format Article
id doaj.art-ab749920f29540d0badb67fccf0e84e7
institution Directory Open Access Journal
issn 2073-4409
language English
last_indexed 2024-03-10T19:35:54Z
publishDate 2020-05-01
publisher MDPI AG
record_format Article
series Cells
spelling doaj.art-ab749920f29540d0badb67fccf0e84e72023-11-20T01:44:41ZengMDPI AGCells2073-44092020-05-0196132210.3390/cells9061322Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug SensitivitySophie Möltgen0Eleonora Piumatti1Giuseppe M. Massafra2Sabine Metzger3Ulrich Jaehde4Ganna V. Kalayda5Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, 53113 Bonn, GermanyDepartment of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, 53113 Bonn, GermanyDepartment of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, 53113 Bonn, GermanyCologne Biocenter, MS Facility, University of Cologne, 50923 Cologne, GermanyDepartment of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, 53113 Bonn, GermanyDepartment of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, 53113 Bonn, GermanyCisplatin is a widely used drug in the treatment of various solid tumors, such as ovarian cancer. However, while the acquired resistance significantly limits the success of therapy, some tumors, such as colorectal cancer, are intrinsically insensitive to cisplatin. Only a small amount of intracellular platinum binds to the target—genomic DNA. The fate of the remaining drug is largely obscure. This work aimed to identify the cytosolic protein binding partners of cisplatin in ovarian and colorectal cancer cells and to evaluate their relevance for cell sensitivity to cisplatin and oxaliplatin. Using the fluorescent cisplatin analog BODIPY-cisplatin, two-dimensional gel electrophoresis, and mass spectrometry, we identified the protein binding partners in A2780 and cisplatin-resistant A2780cis ovarian carcinoma, as well as in HCT-8 and oxaliplatin-resistant HCT-8ox colorectal cell lines. Vimentin, only identified in ovarian cancer cells; growth factor receptor-bound protein 2, only identified in colorectal cancer cells; and glutathione-S-transferase π, identified in all four cell lines, were further investigated. The effect of pharmacological inhibition and siRNA-mediated knockdown on cytotoxicity was studied to assess the relevance of these binding partners. The silencing of glutathione-S-transferase π significantly sensitized intrinsically resistant HCT-8 and HCT-8ox cells to cisplatin, suggesting a possible involvement of the protein in the resistance of colorectal cancer cells to the drug. The inhibition of vimentin with FiVe1 resulted in a significant sensitization of A2780 and A2780cis cells to cisplatin, revealing new possibilities for improving the chemosensitivity of ovarian cancer cells.https://www.mdpi.com/2073-4409/9/6/1322cisplatin resistanceBODIPY-cisplatinoxaliplatinvimentinglutathione-S-transferase πgrowth factor receptor-bound protein 2
spellingShingle Sophie Möltgen
Eleonora Piumatti
Giuseppe M. Massafra
Sabine Metzger
Ulrich Jaehde
Ganna V. Kalayda
Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity
Cells
cisplatin resistance
BODIPY-cisplatin
oxaliplatin
vimentin
glutathione-S-transferase π
growth factor receptor-bound protein 2
title Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity
title_full Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity
title_fullStr Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity
title_full_unstemmed Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity
title_short Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity
title_sort cisplatin protein binding partners and their relevance for platinum drug sensitivity
topic cisplatin resistance
BODIPY-cisplatin
oxaliplatin
vimentin
glutathione-S-transferase π
growth factor receptor-bound protein 2
url https://www.mdpi.com/2073-4409/9/6/1322
work_keys_str_mv AT sophiemoltgen cisplatinproteinbindingpartnersandtheirrelevanceforplatinumdrugsensitivity
AT eleonorapiumatti cisplatinproteinbindingpartnersandtheirrelevanceforplatinumdrugsensitivity
AT giuseppemmassafra cisplatinproteinbindingpartnersandtheirrelevanceforplatinumdrugsensitivity
AT sabinemetzger cisplatinproteinbindingpartnersandtheirrelevanceforplatinumdrugsensitivity
AT ulrichjaehde cisplatinproteinbindingpartnersandtheirrelevanceforplatinumdrugsensitivity
AT gannavkalayda cisplatinproteinbindingpartnersandtheirrelevanceforplatinumdrugsensitivity